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Evaluating the non-evidence based practice of rounding serum creatinine in the
elderly and the impact on medication dosing
Kelly Roden, Pharml) Candidate; Cathy Ramey, PharmD, CGP
Background: The Cockcroft and Gault equation is widely accepted in practice as the
most appropriate way to calculate an estimated creatinine clearance. Geriatric patients
often present with reduced muscle mass, and therefore lower creatinine production, due
to normal changes in body composition associated with aging. Because serum creatinine
and creatinine clearance are inversely proportional using the Cockcroft and Gault
equation, a lower serum creatinine may falsely overestimate renal function in the elderly
population. Rounding to a normal serum creatinine is believed by some practitioners to
prevent over estimation of creatinine clearance and renal function.
Objective: The objective of this study is to identify and compare medications that require
renal dose adjustment when using the patient's measured serum creatinine, if less than 1
mg/dL, versus a rounded serum creatinine of 1 mg/dL in the Cockcroft and Gault
equation.
Methods: Each patient's estimated creatinine clearance was calculated using the patient's
measured serum creatinine and a rounded value of 1 mg/dl, in the Cockcroft and Gault
equation. Once both creatinine clearances had been calculated, an evaluation was
completed to determine how many of the patient's medications required renal dose
adjustment based on either the measured or rounded creatinine clearance. The number of
dosing discrepancies was then assessed, in addition to creatinine clearance values, to look
for trends or patterns regarding the amount of dosing discrepancies and the effects of
rounding to a serum creatinine of 1 mg/dL.
Results: A total of 32 patients (6 male, 26 female) were evaluated for renal dose
adjustments based on the measured and rounded creatinine clearance. Seven patients
were identified as having discrepancies, all of which were female patients. 'lhe average
difference between the measured and rounded creatinine clearance in female patients was
16 ml.zmin. A total of 12 discrepancies were found affecting 9 different medications.
The average number of discrepancies per patient that presented with a discrepancy was
1.71 discrepancies. Five of the 12 discrepancies affected both the measured creatinine
clearance and the rounded creatinine clearance, while 7 of the 12 discrepancies affected
only the rounded creatinine clearance.
Conclusion: Results of the study show that patients in CI(D Stage 3. or in CKD Stage 2
but within approximately 16 rnl.zrnin of CKD Stage 3~are 1110relikely to present with
renal dosing discrepancies, and that the discrepancies identified were not localized to
particular medications or therapeutic areas.
Word Count: 2248
Key Phrases: serum creatinine. creatine clearance, elderly, renal dosing discrepancies
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BACKGROUND
Physiologically, muscle tissue uses creatine, a nutrient produced primarily by the
liver and kidneys, as a source of energy. The breakdown of creatine by muscle tissue
results in a waste product called creatinine. Creatinine is then released from muscle
tissue into the blood stream and cleared, almost exclusively, by the kidneys. As a result,
creatinine clearance can be used to assess renal function. The Cockcroft and Gault
equation is widely accepted in practice as the most appropriate way to calculate an
estimated creatinine clearance and is the standard equation used for drug dosage
adjustments.' This equation accounts for the patient's age, ideal body weight, gender,
and serum creatinine level. Over time, it has been adapted into practice to use the
patient's actual body weight when it is less than the patient's ideal body weight. The
following is the Cockcroft and Gault equation:
CrCI (mLimin) = [(140 - age) x IBW (x 0.85 for females)] / (SCr x 72).
Normal serum creatinine levels in adults range from 0.6-1.2 mg/dL. Geriatric
patients often present with reduced muscle mass, and therefore lower creatinine
production, due to normal changes in body composition associated with aging. Because
serum creatinine and creatinine clearance are inversely proportional using the Cockcroft
and Gault equation, a lower serum creatinine indicates a higher creatinine clearance and
increased renal function. A normal creatinine clearance ranges from 90 to 130 mLimin.
Questions have arisen about how to assess renal function in geriatric patients using the
Cockcroft and Gault equation when low serum creatinine is due to decreased muscle
mass and not due to increased renal creatinine clearance.
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Accurately estimating renal function in this population is imperative for proper
dosing. Both over and under dosing medications have consequences that impact quality
of care and patient outcomes. For example, a patient presenting with decreased muscle
mass, decreased serum creatinine, and decreased renal function may have an estimated
creatinine clearance that appears normal via the Cockcroft and Gault equation. Over-
dosing of medications in this patient increases the risk for adverse drug effects and
toxicities. In practice, some clinicians routinely round a serum creatinine level of less
than 1 mg/dL to 1 mg/dL for use in the Cockcroft and Gault equation in older adults.
Rounding to a normal serum creatinine is believed by some to more accurately predict
renal function and prevent over estimation of creatinine clearance and renal function.
PREVIOUS STUDIES
Hu et al assessed the relationship between estimating creatinine clearance and
drug dosing errors in the elderly and found that patients with a lower estimated creatinine
clearance experienced more dosing errors and that "physicians routinely overestimate
renal function in older patients.:" This overestimation of renal function is a result of
using measured serum creatinine levels in the Cockcroft and Gault equation when
decreased measured serum creatinine is not a result of sufficient renal function, but rather
a result of reduced muscle mass. The practice of rounding to 1 111g/dLhas been adapted
to prevent this overestimation, although it is not an evidence based method. However,
there are other studies that assess the practice of rounding the SerU111creatinine to 1
mg/dL and the results have not proven to be better at accurately assessing renal function.
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Dowling et al found that using a rounded serum creatinine of 1 mg/dL, as opposed
to a measured serum creatinine, lead to a significantly lower estimation of creatinine
clearance when using the Cockcroft and Gault cquation.f In addition, when both
estimates were compared to a patient's actual creatinine clearance via 24 hour urine
collection, the rounded value more significantly underestimated renal function. This
study recommends that the practice of rounding be avoided due to the underestimation of
renal function which leads to sub-therapeutic dosing errors.r' This recommendation is
further supported by Smythe et al. However, Smythe also addressed the degree of the
measured serum creatinine below 1 mg/dL and the impact on estimating creatinine
clearance. The study found that "bias was greater and precision less when Ser
concentrations of < 0.7 mg/dL were rounded than when Ser concentrations of> 0.7
mg/dL were rounded. Furthermore, "a consistent effect on precision of rounding the SCr
concentration was not evident.,,4
NEED FOR FURTHER STUDY
There is an ongoing need to assess the clinical practice of rounding serum
creatinine to 1 mg/dL in geriatric patients and its effects on accurately estimating renal
function. This non-evidence based practice can lead to dosing errors for medications
requiring renal dose adjustments. There is need to study the prevalence of dosing errors
when assessing patients renal function from calculating an estimated creatinine clearance
frOITImeasured serum creatinine versus rounded serum creatinine. Furthermore, there is a
need for establishing evidence based guidelines for when rounding may be considered
appropriate. Although the objective of this study is not to establish guidelines, there will
be an evaluation of C0111mOn medications with dose discrepancies.
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OBJECTIVE
The objective of the study is to evaluate geriatric patients at a designated long
term care facility in Indiana. For those patients with a serum creatinine less than 1
mg/dL, a review will be completed to assess how many of their current medications
require renal dosage adjustment using their measured serum creatinine versus a SerUlTI
creatinine rounded to 1 mg/dL in the Cockcroft and Gault equation. The number of
medications that require dosage adjustment using both methods will be compared.
Common medications that present discrepancies in renal dose adjustment when
comparing measured vs. rounded serum creatinine will be identified.
Here after, the estimated creatinine clearance calculated using the patient's
measured serum creatinine value in the Cockcroft and Gault equation will be referred to
as the measured creatinine clearance; similarly, the estimated creatinine clearance
calculated using a rounded serum creatinine value of 1 mg/dl. in the Cockcroft and Gault
equation will be referred to as the rounded creatinine clearance.
METHODS
This study is a retrospective chart review of geriatric patients residing in the
Brownsburg Health Care Center, a long term care facility in Indiana. Inclusion criteria
for this study are patients residing in the long term care facility, patients age 65 and older,
patients with a measured serum creatinine of less than 1 mg/dL, and patients receiving at
least one scheduled medication. Exclusion criteria for this study are patients on dialysis,
patients with any form of amputation, patients with a serum creatinine greater than or
equal to 1 mg/dl.., and patients with a height less than or equal to 60 inches. Only
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scheduled medications (including oral medications, injectable medications, and patches)
were evaluated. This study excluded all "as needed" medications, topical medications
(including creams, ointments, ear/eye drops, enemas, etc.), inhalers and aerosol solutions,
and multivitamins. This study received IRB approval through Butler University due to
collection of patient information including: age, gender, height, weight, serum creatinine,
and current medications. Once all data were collected, each patient's estimated creatinine
clearance was calculated using the Cockcroft and Gault equation using both the patient's
measured serum creatinine and a rounded value of 1 mg/dL. Once both creatinine
clearances had been calculated, an evaluation was completed to determine how many
medications of the patient's current medications required renal dose adjustment based on
either the measured or rounded creatinine clearance. The number of dosing discrepancies
was then assessed, in addition to creatinine clearance values, to look for trends or patterns
regarding the amount of dosing discrepancies and the effects of rounding to a serum
creatinine of 1 mg/dL.
RESULTS
Patient Characteristics
A total of 89 patients were residing in the Brownsburg Health Care Center at the
time of data collection. Of that, 32 patients met the study criteria and were subject to
evaluation. The population group was predominately female with 26 females of the 32
total patients (81.25%). The average age in years and average number of medications for
female patients was 78.5 and 9.7 respectively. Furthermore. the average difference
between the measured and rounded creatinine clearance was 16 111L)111in for female
patients. Figure 1 details all the patient characteristics and the comparisons between the
male and female patients.
Discrepancies
Of the 32 patients evaluated, 7 patients presented with renal dosing discrepancies.
All 7 patients that presented with discrepancies were female. Among the 7 female
patients, a total of 12 discrepancies were identified giving an average of 1.71
discrepancies per patient. The 12 discrepancies presented from 9 various medications.
Seven of the 12 discrepancies (58.3%) affected only the rounded creatinine clearance,
while 5 of the 12 discrepancies (41.7%) affected both the measured and rounded
creatinine clearance. Additionally, the discrepancies presented with a variety of renal
dosing recommendations including recommendations to: decrease dose (4/12; 33.3%),
decrease frequency (3/12; 25%), decrease dose and frequency (1/12; 8.3%), and decrease
dose or frequency (1112; 8.3%). Furthermore, 3 of the 12 discrepancies (25%) identified
that the medication was contraindicated based of the patient's renal function. A full list
of the n1edications, discrepancies, and dosage recommendations can be found in Figure 2.
Further analysis was done to identify if there was any relationship between the
discrepancies and creatinine clearance values. Three of the 7 patients that presented wi th
a discrepancy had a measured creatinine clearance> 60 mLimin; however, this value was
then reduce to 30-60 mL/min after calculating the patient's rounded creatinine clearance.
The remaining 4 patients that presented with discrepancies had a measured creatinine
clearance of 30-60 111L/min, and the rounded creatinine clearance remained in that range.
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A full depiction of the breakdown of patients by creatinine clearance ranges can be seen
in Figure 3.
DISCUSSION
Creatinine Clearance Values
The creatinine clearance ranges detailed in Figure 3 were identified to give insight
into the Chronic Kidney Disease (CKD) Stage of the patient, whether that patient's CKD
Stage would change after calculating a rounded creatinine clearance, and if there was any
relationship between the patients that presented with discrepancies and their CKD Stage.
The CKD Stages, as defined by the KDOQI Clinical Practice Guidelines are as follows:
Stage 1 (normal function; > 90 mUmin), Stage 2 (mild dysfunction; 60-89 mUmin),
Stage 3 (moderate dysfunction; 30-60 mUmin), Stage 4 (severe dysfunction; 15-30
mUmin), and Stage 5 (failure; < 15 ml.zmin)." The 3 patients that presented with
discrepancies and a measured creatinine clearance> 60 mUmin (as seen in Column 2 of
Figure 3) would be categorized into CKD Stage 1 or 2 depending on the patient's exact
creatinine clearance value; however, these patient were then re-categorized into CKD
Stage 3 after calculating a rounded creatinine clearance of 30-60 mUmin. Keeping in
mind that the average difference between the measured and rounded creatinine clearance
for female patients identified in this study was 16 mUmin, then patients with a measured
creatinine clearance between approximately 60-76 ml.zrnin in CKD Stage 2 would be at
the highest risk for being re-categorized into CKD Stage 3. The remaining 4 patients that
presented with discrepancies (as seen in Column 3 of Figure 3) met the criteria for CKD
Stage 3 based on both the measured and rounded creatinine clearances. These findings
give insight to practitioners that patients in CKD Stage 3, or in CKD Stage 2 but within
approximately 16 mL/min of CKD Stage 3, are more likely to present with renal dose
discrepancies. This helps identify for which patients it may be beneficial to calculate
both a measured and rounded creatinine clearance using the Cockcroft and Gault equation
and evaluate the risks and benefits of the different renal dosing recommendations.
Clinical implications
A practitioner's decision to use a measured vs. rounded creatinine clearance
to determine renal dosing of medications can ultimately affect the patient and the quality
of their care. The following are examples of medications that were identified in this
study as having discrepancies and the clinical implications of the renal dose adjustment
recommendation. Keppra (Levetiracetam) was identified as having a discrepancy
between the prescribed dosage and both the measured and rounded creatinine clearances.
The renal dose adjustment recommendation is to decrease the frequency of
administration. If that recommendation is accepted, the patient may be at an increased
risk of inadequate seizure management; conversely, if the recommendation is declined
and the practitioner continues the prescribed dose, the patient may be at an increased risk
of central nervous system and cardiovascular side effects." Similarly, Viread (Tenofovir).
a medication indicated for the treatment of HIV or Hepatitis C, was identified as having a
discrepancy between the prescribed dosage and the rounded creatinine clearance. If the
practitioner uses the measured creatinine clearance. then there is no dose adjustment
required. However, if the practitioner uses the rounded creatinine clearance, the renal
dose adjustment recommendation is to decrease the frequency of administration. Ir that
recommendation is accepted, the patient may be at an increased risk of inadequate vira]
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suppression and disease progression; conversely, if the recommendation is declined and
the practitioner continues the prescribed dose, the patient may be at an increased risk of
central nervous system and endocrine side effects." In summary, the clinical implications
of implementing the renal dose adj ustment recommendations must be carefully
considered for patients that present with discrepancies, and clinical judgement must be
made on a case-by-case basis. A full list of the medications, discrepancies, and dosage
recommendations can be found in Figure 2 and more examples of clinical implications
can be found in Figure 4.
CONCLUSION
In conclusion, the results of this study show that patients in CKD Stage 3, or in
CKD Stage 2 but within approximately 16 mL/min of CKD Stage 3, are 1110relikely to
present with renal dosing discrepancies, and that the discrepancies identified were not
localized to particular medications or therapeutic areas.
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Figure 1 - Patient Characteristics
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Figure 2 - Discrepancies
.. .. .
Keppra
(Levetiracetam)
Macrobid
(Nitrofurantoin)
Macrobid
(Nitrofurantoin)
Pepcid
(Famotidine)
Lyrica
(Pregabalin)
Zantac
(Ranitidine)
Zantac
(Ranitidine)
Aldactone
(Spironolactone)
Aldactone
(Spironolactone)
Viread
(Tenofovir)
Combivir
(Lamivudinel
Zidovudine)
Januvia
(Sitagliptin)
Dosage .. ...- R-CrCI Dosage
Recom mendation-. .....
500mg po TID 250-750mg po BID 2S0-750mg po BID
100mg po QHS Contraindicated Contrai ndicated
100mg po BID x 10 Contraindicated Contraindicated
days
20mg po BID N/A Administer 50% of dose or
increase to q 36-48 hrs
100mg po BID N/A 50mgpo BID
300mg po QHS 150mg po daily 150mg po daily
150mg po BID N/A 150mg po daily
50mg po daily 12.5-25mg po daily 12.5-25mg po daily
50mg po BID N/A 12.5-25mg po daily
300mg po daily N/A 300mg po q 48 hrs
150/300mg po BID N/A Fixed-dose combination
product not recommended
100mg po daily N/A 50mg po daily
M-CrCI = Measured Creatinine Clearance; R-CrCI = Rounded Creatinine Clearance
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Figure 3 - Measured vs. Rounded Creatinine Clearance Ranges
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Figure 4 - Clinical Implications
Drug
Keppra ! Frequency Risk of inadequate i Risk of eNS and
seizure management CVeffects
Macrobid Contraindicated NewABX
Untreated UTI
Lyrica !Dose Risk of inadequate i Risk of eNS
pain, seizures, etc. effects
management
Viread L Frequency Risk of inadequate i Risk of eNS and
viral suppression endocrine effects
Januvia !Dose Risk of inadequate i Risk of ADRs
blood glucose control
Recommendation Accept Decline
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